A Phase III Multicenter, Double-blind, Placebo-controlled, Study Evaluating the Safety, and Efficacy of STR001 Treatment in Adults With Sudden Sensorineural Hearing Loss
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2018
At a glance
- Drugs Pioglitazone (Primary) ; Pioglitazone (Primary)
- Indications Hearing loss
- Focus Registrational; Therapeutic Use
- Acronyms RESTORE
- Sponsors Strekin
- 09 Oct 2018 Status changed from not yet recruiting to recruiting, as reported in a Strekin media release.
- 09 Oct 2018 According to a Strekin media release, the trial is expected to report results in late 2019.
- 31 Aug 2018 Biomarkers information updated